https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Tue, 25 Jan 2022 12:51:02 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/6avlde9a4fu-ata3219-ata3271-ata188-t-cell-immunotherapy-products-in-development/ Mon, 29 Nov 2021 11:36:56 +0000 http://13.40.107.223/video/6avlde9a4fu-ata3219-ata3271-ata188-t-cell-immunotherapy-products-in-development/ Pascal Touchon, President & CEO, Atara Biotherapeutics, San Francisco, CA, describes the pipeline of Atara Biotherapeutics including the ATA3219, an anti-CD19 allogeneic T-cell immunotherapy targeting B-cell malignancies, as well as ATA3271, a chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin for solid tumors. He additionally discusses the latest results from the Phase I/II EMBOLD study (NCT03283826) of ATA188, a T-cell immunotherapy that targets Epstein-Barr virus (EBV) in patients with progressive multiple sclerosis. This interview took place at Meeting on the Mesa 2021.

]]>